MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced that it has named Dr. David B. DeLurgio as
the national principal investigator (PI) for the CONVERGE IDE clinical
trial.
Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in
Atlanta, GA. He is Director of Electrophysiology at the Emory Heart and
Vascular Center at Emory St. Joseph’s Hospital, a role he has served in
since 2014. Dr. DeLurgio earned his medical degree from the University
of California Los Angeles School of Medicine, and completed a fellowship
in Cardiac Electrophysiology at Emory University School of Medicine. He
originally joined Emory Healthcare in 1996 and served as Director of the
Arrhythmia Center and Electrophysiology Lab at Emory University Hospital
Midtown.
“I am honored and humbled to be given this opportunity to serve as the
national PI for the CONVERGE trial,” said Dr. DeLurgio. “This landmark
study is critically important research in the field of cardiac
electrophysiology. At Emory, we have adopted the Convergent approach and
have experienced first-hand the results of this therapy. Now, I’m
looking forward to taking a leadership role and partnering with other
trial sites to quickly enroll patients and complete the trial.”
The CONVERGE IDE trial is a landmark prospective, randomized trial
comparing the Convergent approach to endocardial catheter ablation for
patients with persistent or long-standing persistent Afib. The
Convergent approach is a multi-disciplinary therapy in which a
closed-chest epicardial ablation is performed by a surgeon, and then
complemented by an endocardial catheter ablation performed by an
electrophysiologist. In addition to the ongoing IDE trial, individual
center results have been published in numerous peer reviewed papers.
“We are very excited about having Dr. DeLurgio serve in this role,” said
Mike Carrel, AtriCure’s President and Chief Executive Officer. “Momentum
in the CONVERGE trial continues to build as we add new sites and launch
various patient recruitment initiatives. We are looking forward to
building on this momentum with the leadership of Dr. DeLurgio.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial
Appendage Exclusion System products are the most widely sold LAA
management devices worldwide, with more than 100,000 implanted to date.
For more information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005300/en/
Source: AtriCure, Inc.
AtriCure, Inc.
Media Relations
Valerie Storch-Willhaus,
612-605-3311
Director, Corporate Marketing and Communications
vstorch-willhaus@atricure.com
or
Investor
Relations
Andy Wade, 513-755-4564
Senior Vice President and
Chief Financial Officer
awade@AtriCure.com
